WHAT IS CLAIMED AS NEW AND IS DESIRED TO BE SECURED BY LETTERS PATENT OF THE UNITED STATES IS:

1. A method of treating or preventing a disease caused by seretonin comprising administering effective amount of a piperidine derivative of general formula (I) or pharmaceutically acceptable salt thereof:



(I)

wherein A^1 represents an unsubstituted or substituted pyridyl, piperidyl, piperidino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino or piperazinyl group, a substituted alkyl group having from 1 to 8 carbon atoms, a substituted cycloalkyl group having from 4 to 8 carbon atoms, or an unsubstituted or substituted alkoxyl group having 1 to 8 carbon atoms,

X^1 is a hydrogen atom or a halogen atom,

Y^1 is -CONH-, -NHCO-, $-CONHCH^2-$, $-(CH_2)_n-$ or -COO-, wherein n is an integer of from 0 to 4, and

Z^1 is -CH=CH-, $-S-CH_2-$, -S- or $-CH_2-CH_2-$.

2. The composition of claim 1, wherein A^1 has a substituent and said substituent is

R^1-CO- or $R^2-N(R^3)-$

wherein R^1 is a hydrogen atom, an alkyl or alkoxyl group having from 1 to 6 carbon atoms, an amino group which may be substituted by an alkyl group having from 1 to 6 carbon atoms, or an acylaminoalkyl group having from 1 to 6 carbon atoms, and

R^2 and R^3, which may be the same or different, each represents a hydrogen atom, an alkyl, acyl or alkoxycarbonyl group having from 1 to 6 carbon atoms, or an aminocarbonyl group which may be substituted by an alkyl group having from 1 to 6 carbon atoms.

3. The method of claim 1, wherein said substituent on A^1 is formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-formylglycyl, N-acetylglycyl, N-formyl-β-alanyl, N-acetyl-β-alanyl, N-methyl-N-formyl, N-methyl-N-acetyl, N-methyl-N-propionyl, N-ethyl-N-formyl or N-ethyl-N-acetyl.

4. The method of claim 1, wherein Y^1 is a -CONH-.

5. The method of claim 1, wherein Z^1 is a -CH=CH-.

6. The method of claim 1, wherein the piperidine derivative is 1-formyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1piperidinyl))ethylisonipecotamide.

7. A method of treating or preventing platelet aggregation comprising administering an effective amount of a piperidine derivative of the formula (I) or a salt thereof or an active ingredient of a pharmaceutical composition:



(I)

wherein A^1 represents an unsubstituted or substituted pyridyl, piperidyl, piperidino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino or piperazinyl group, a substituted alkyl group having from 1 to 8 carbon atoms, a substituted cycloalkyl group having from 4 to 8 carbon atoms, or an unsubstituted or substituted alkoxyl group having 1 to 8 carbon atoms,

X^1 is a hydrogen atom or a halogen atom,

Y^1 is -CONH-, -NHCO-, $-CONHCH^2-$, $-(CH_2)_n-$ or -COO-, wherein n is an integer of from 0 to 4, and

Z^1 is -CH=CH-, $-S-CH_2-$, -S- or $-CH_2-CH_2-$.

8. The method of claim 7, wherein the piperidine derivative is 1-formyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1piperidinyl))ethylisonipecotamide.

9. A piperidine derivative represented by the general formula (II) or a salt thereof:



(II)

wherein A^2 represents an unsubstituted or substituted piperidino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino or piperazinyl group, a substituted alkyl group having from 1 to 8 carbon atoms, a substituted cycloalkyl group having from 4 to 8 carbon atoms, or an unsubstituted or substituted alkoxyl group having 1 to 8 carbon atoms,

wherein suitable substituents include:

R^4-CO- or R^5-N-
|
R^6

wherein R^4 represents an alkyl or alkoxyl group having from 1 to 6 carbon atoms, an amino group which may be substituted by an alkyl group having from 1 to 6 carbon atoms, or an acylaminoalkyl group having from 1 to 6 carbon atoms.

R^5 and R^6, which may be the same or different, each represents a hydrogen atom, an alkyl, acyl or alkoxycarbonyl group having from 1 to 6 carbon atoms, or an aminocarbonyl group which may be substituted by an alkyl group having from 1 to 6 carbon atoms, and

X^2 is a hydrogen atom or a halogen atom,

Y^2 is -CONH-, -NHCO-, -CONHCH^2-, -$(CH_2)_n$- or -COO-,

wherein n is an integer of from 0 to 4, and

Z^2 is -CH=CH-, -S-CH_2-, -S- or -CH_2-CH_2-.

10. The piperidine derivative of claim 9, wherein A^2 is substituted with a substituent selected from the group consisting of acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, carbamoyl, N-methylcarbamoyl, N-

ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-formylglycyl, N-acetylglycyl, N-formyl-β-alanyl, N-acetyl-β-alanyl, N-methyl-N-formyl, N-methyl-N-acetyl, N-methyl-N-propionyl, N-ethyl-N-formyl, and N-ethyl-N-acetyl.

11. The piperidine derivative of claim 9, wherein Y^2 is a group -CONH-.

12. The piperidine derivative of claim 9, wherein Z^2 is a group -CH=CH-.

13. A compound selected from the group consisting of

1-methoxycarbonyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)1-piperidinyl))ethylisonipecotamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethylisonipecotamide,

1-acetyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethylisonipecotamide,

1-t-butoxycarbonyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1piperidinyl))ethylisonipecotamide,

1-carbamoyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethylisonipecotamide,

1-(N,N-dimethylcarbamoyl)-N-(2(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1piperidinyl))ethylisonipecotamide,

1-(N-acetylglycyl)-N-(2-(4(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1piperidinyl))ethylisonipecotamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidinyl))ethylpipecolamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-(N-acetyl)pipecolamide,

1-formyl-4-((2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethylcarbamoyl)piperazine,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-aminocyclohexanecarboxamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-acetylaminocyclohexanecarboxamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-(1-t-butoxycarbonylamino)cyclohexanecarboxamide,

4-5H-dibenzo[a,d]cyclohepten-5-ylidene))1-2-ethoxycarbonylamino)ethyl)piperidine,

4-(5H-dibenzo[a,d]cyclohepten-5-ylidene-1-(2-t-butoxycarbonylamino)ethyl)piperidine,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-1-(1-amino)cyclohexanecarboxamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-1-(1-acetylamino)cyclohexanecarboxamide,

N-(2-(4-(5H-dibenzo [a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-1-(1-t-butoxycarbonylamino)cyclohexanecarboxamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-1-(formylamino)cyclohexanecarboxamide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-1-(1-N,N-dimethylcarbamoylamino)cyclohexanecarboxamide,

N-(2-(4-(5Hdibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-aminobutyramide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidinyl))ethyl-4-formylaminobutyramide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-acetylaminobutyramide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-t-butoxycarbonylaminobutyramide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-(N,N-dimethylcarbamoylamino)butyramide,

N-(2(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-(N-methylamino)butyramide,

N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethyl-4-(N-methyl-t-butoxycarbonylamino)butyramide,

1-formyl-N-(3-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))propylisonipecotamide,

4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1(3-t-butoxycarbonylaminopropyl)piperidine,

1-(3-aminopropyl)-4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine,

1-formyl-isonipecotic acid 2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)) ethyl ester,

1-(2-aminoethyl)-4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine,

4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-(2-t-

butoxycarbonylamino)ethyl)piperidine,

1-formyl-N-(2-(4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl))ethylisonipecotamide,

1-(2-aminoethyl)-4-(9-thioxanthinidene)piperidine,

4-(9-thioxanthinidene)-1-((2-t-butoxycarbonylamino)ethyl) piperidine,

1-formyl-N-(2-(4-(9-thioxanthinidene)piperidinyl)) ethylisonipecotamide,

1-formyl-N-(2(4-(11-H-dibenzo[b,e]thiepin-2-fluoro-11-ylidene)-1-piperidinyl))ethylisonipecotamide,

1-(4-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)butyl)morpholine,

1-(4-(4-(5H-dibenzo[a,d]cyclohepten-5ylidene)-1-piperidinyl)butyl)thiomorpholine,

1-(4-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)pentyl)morpholine,

1-(4-(4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)butyl)piperidine and

1-(4-(4-(9-thioxanthilidene)piperidinyl)butyl)morpholine.